Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reveal a strong consensus that rosiglitazone increases cardiovascular risks, supported by references to landmark studies and meta-analyses from reputable sources like NEJM. The tone ranges from factual and analytical to critical, emphasizing the drug's long-standing safety concerns and regulatory consequences, which underscores the importance of the research in shaping medical guidelines.
Most comments acknowledge the risks associated with rosiglitazone, reflecting a consensus on its cardiovascular dangers.
Discussions show high engagement with the topic, referencing multiple studies, meta-analyses, and regulatory responses.
Posts include detailed mentions of specific research, historical context, and policy changes, demonstrating moderate to deep involvement.
The discussions highlight significant concerns about drug safety, regulatory decisions, and implications for clinical practice, indicating considerable impact.
NEJM famously does not publish meta-analysis (sure @mikejohansenmd approves - MA are for twitter) but the most famous MA was in NEJM https://t.co/Vr7d84uBIy (for fun, see this @kaulcsmc critique of this https://t.co/wyTLq3tCxd) FDA sadly has got rid of the DM guidance since
Decade on The Nissen review of Rosiglitazone had a lasting impact on diabetes care. The CVOT data has helped Cost have been added. Time to debate @kamleshkhunti @Nirantharakumar @AbdTahrani @AmarPut @drpatrickholmes https://t.co/8xb6agXHT0
5/ In 2007, Nissen and Wolski @ClevelandClinic published a @NEJM paper using data from trials+@US_FDA website showing that Rosiglitazone caused ⬆️ MI & CV death. Rosiglitazone was the most widely sold oral hypoglycemic at that time. https://t.co/oCQyUIdsgJ
the FDA created the need for outcomes trials have the rosiglitazone debarcle https://t.co/7y1BGXQRIz ironically this has given us new SGLT2i and GLP1 treatments by serendipity now they are minded to cancel this recommendation I wonder what @drjohnm thinks of this... https://t.co/ZCow9691bj
@DFCapodanno Maybe wrong, but I do remember this one at the last CV meta-analysis published on NEJM: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | New England Journal of Medicine https://t.co/p90OhF2GZV
@BumblebeeJoe Avandia/rosiglitazone was ook goed voor 100.000 doden: https://t.co/dAthzlWhhw Maar corona/griep modRNA is toch wel meest effectief gebleken om mensen om te leggen: 35 miljoen wereldwijd TOT NU TOE: https://t.co/IW2GpaDeXx https://t.co/lKhM3hijDA
This week, John Mandrola MD examines the implications of incidental CAC findings on chest CT scans and discusses the relationship between elevated CAC scores and cardiovascular risk. The importance of exercise benefits…
This video explores the surprising findings from the ACCORD trial, revealing that targeting an HbA1c below 6 increased mortality compared to standard targets. Learn about the study design, key results, and the…
@DFCapodanno Maybe wrong, but I do remember this one at the last CV meta-analysis published on NEJM: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | New England Journal of Medicine https://t.co/p90OhF2GZV
@BumblebeeJoe Avandia/rosiglitazone was ook goed voor 100.000 doden: https://t.co/dAthzlWhhw Maar corona/griep modRNA is toch wel meest effectief gebleken om mensen om te leggen: 35 miljoen wereldwijd TOT NU TOE: https://t.co/IW2GpaDeXx https://t.co/lKhM3hijDA
@JasonConnorPhD Few examples
@conkyan @ABridgen https://t.co/NfFapAPCh6
In 2007 an article was published in NEJM which showed that rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes. https://t.co/fYRLSkkeqs
RT @theoceanlawyers: NE Journal of Medicine study linked Avandia to a 43% increased risk of heart attacks, and a 64% increased risk of deat…
NE Journal of Medicine study linked Avandia to a 43% increased risk of heart attacks, and a 64% increased risk of death from heart disease. Avandia is still FDA approved and available in the U.S. https://t.co/oTelYOHBCW
RT @hswapnil: NEJM famously does not publish meta-analysis (sure @mikejohansenmd approves - MA are for twitter) but the most famous MA was…
RT @hswapnil: NEJM famously does not publish meta-analysis (sure @mikejohansenmd approves - MA are for twitter) but the most famous MA was…
El cual por cierto se puede seguir leyendo a día de hoy: https://t.co/6eXGCepJoj
Se siguieron publicando más estudios sobre beneficios y tímidas apreciaciones de riesgo CV hasta que en 2007 los doctores Nissen y Wolski publicaron el meta-analisis titulado: "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes"
RT @hswapnil: NEJM famously does not publish meta-analysis (sure @mikejohansenmd approves - MA are for twitter) but the most famous MA was…
RT @hswapnil: NEJM famously does not publish meta-analysis (sure @mikejohansenmd approves - MA are for twitter) but the most famous MA was…
NEJM famously does not publish meta-analysis (sure @mikejohansenmd approves - MA are for twitter) but the most famous MA was in NEJM https://t.co/Vr7d84uBIy (for fun, see this @kaulcsmc critique of this https://t.co/wyTLq3tCxd) FDA sadly has got rid of the DM guidance since
@conazole @Clara_Locher https://t.co/bEevWWAVKA.
RT @DrDerekConnolly: the FDA created the need for outcomes trials have the rosiglitazone debarcle https://t.co/7y1BGXQRIz ironically this…
the FDA created the need for outcomes trials have the rosiglitazone debarcle https://t.co/7y1BGXQRIz ironically this has given us new SGLT2i and GLP1 treatments by serendipity now they are minded to cancel this recommendation I wonder what @drjohnm thinks of this... https://t.co/ZCow9691bj
RT @JoshuaDWallach: Avandia, a @GSK drug, was approved ~20 years ago for the treatment of #diabetes. Since that time, numerous studies have…
Avandia, a @GSK drug, was approved ~20 years ago for the treatment of #diabetes. Since that time, numerous studies have highlighted cardiovascular safety concerns about Avandia: https://t.co/GykeZcutyO https://t.co/yuzYhON0Ro 2/9
RT @docwas: Decade on The Nissen review of Rosiglitazone had a lasting impact on diabetes care. The CVOT data has helped Cost have been add…
RT @docwas: Decade on The Nissen review of Rosiglitazone had a lasting impact on diabetes care. The CVOT data has helped Cost have been add…
RT @docwas: Decade on The Nissen review of Rosiglitazone had a lasting impact on diabetes care. The CVOT data has helped Cost have been add…
Decade on The Nissen review of Rosiglitazone had a lasting impact on diabetes care. The CVOT data has helped Cost have been added. Time to debate @kamleshkhunti @Nirantharakumar @AbdTahrani @AmarPut @drpatrickholmes https://t.co/8xb6agXHT0
RT @mbelshazly: 5/ In 2007, Nissen and Wolski @ClevelandClinic published a @NEJM paper using data from trials+@US_FDA website showing that…
5/ In 2007, Nissen and Wolski @ClevelandClinic published a @NEJM paper using data from trials+@US_FDA website showing that Rosiglitazone caused ⬆️ MI & CV death. Rosiglitazone was the most widely sold oral hypoglycemic at that time. https://t.co/oCQyUIdsgJ
@mbeisen @mbalter @MaxKennerly @SteveSprieser @barnoolut @JoeySchmittPhD @GMWatch @Thesciencevort1 @kevinfolta @BrianHMathison @eugenegu @sethquimby1 @Twitter @sciencemagazine @Bayer @IARCWHO @ACSHorg But that drug got approved and was on the market for around a decade. Until people got suspicious and started to actually pay attention. Surprise! Science: https://t.co/TBDqgogLeW
@VladoPerkovic I see a lot of chance and serendipity* involved to get to one of the few times that post-approval clinical outcome studies were done well. *Rosiglitazone SR/MA finding a signal for harm that wasn't born out in subsequent large RCT. https://t.co/UvBNLyNboV https://t.co/Mx5vSWmVCF
SS
PH
ME
PC
RP
HD
SK
TB
DS
JS
MB
GZ
RM
MM
AP
HC
F
DF
FN
JW
DP
MK
PH
M
PT
LP